L. Mansó Sánchez

Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)

J. Pérez-Fidalgo, A. Oaknin, A. Redondo, 2021, ESMO open.

Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience

M. Martín, J. García-Saenz, J. A. Guerra Martínez, 2019, Clinical and Translational Oncology.

Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.

Bing-he Xu, L. Dirix, A. Awada, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: a stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601

J. Pérez-Fidalgo, A. Oaknin, A. Redondo, 2023, International Journal of Gynecological Cancer.